 Cost-Benefit Analysis
"Cost-Benefit Analysis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. Cost effectiveness compares alternative ways to achieve a specific set of results.
| Descriptor ID |
D003362
|
| MeSH Number(s) |
N03.219.151.125
|
| Concept/Terms |
Cost-Benefit Analysis- Cost-Benefit Analysis
- Analyses, Cost-Benefit
- Analysis, Cost-Benefit
- Cost-Benefit Analyses
- Cost Benefit Analysis
- Analyses, Cost Benefit
- Analysis, Cost Benefit
- Cost Benefit Analyses
Cost-Utility Analysis- Cost-Utility Analysis
- Analyses, Cost-Utility
- Analysis, Cost-Utility
- Cost Utility Analysis
- Cost-Utility Analyses
Economic Evaluation- Economic Evaluation
- Economic Evaluations
- Evaluation, Economic
- Evaluations, Economic
Marginal Analysis- Marginal Analysis
- Analyses, Marginal
- Analysis, Marginal
- Marginal Analyses
Cost Benefit- Cost Benefit
- Costs and Benefits
- Benefits and Costs
|
Below are MeSH descriptors whose meaning is more general than "Cost-Benefit Analysis".
Below are MeSH descriptors whose meaning is more specific than "Cost-Benefit Analysis".
This graph shows the total number of publications written about "Cost-Benefit Analysis" by people in this website by year, and whether "Cost-Benefit Analysis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 | | 1996 | 0 | 2 | 2 | | 1997 | 0 | 4 | 4 | | 1998 | 0 | 6 | 6 | | 1999 | 0 | 2 | 2 | | 2000 | 1 | 6 | 7 | | 2001 | 0 | 6 | 6 | | 2002 | 0 | 5 | 5 | | 2003 | 0 | 4 | 4 | | 2004 | 0 | 5 | 5 | | 2005 | 2 | 14 | 16 | | 2006 | 0 | 12 | 12 | | 2007 | 0 | 12 | 12 | | 2008 | 0 | 5 | 5 | | 2009 | 0 | 18 | 18 | | 2010 | 0 | 11 | 11 | | 2011 | 0 | 16 | 16 | | 2012 | 1 | 26 | 27 | | 2013 | 1 | 13 | 14 | | 2014 | 2 | 25 | 27 | | 2015 | 3 | 29 | 32 | | 2016 | 5 | 24 | 29 | | 2017 | 9 | 14 | 23 | | 2018 | 6 | 22 | 28 | | 2019 | 5 | 23 | 28 | | 2020 | 6 | 26 | 32 | | 2021 | 3 | 25 | 28 | | 2022 | 1 | 15 | 16 | | 2023 | 0 | 9 | 9 | | 2024 | 8 | 11 | 19 | | 2025 | 0 | 6 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Cost-Benefit Analysis" by people in Profiles.
-
Doan TT, Hutton DW, Wright DR, Prosser LA. Cost-Effectiveness of Universal Routine Depression Screening for Adolescents in Primary Care. JAMA Health Forum. 2025 May 02; 6(5):e250711.
-
Sanders J, Greenhawt M, Oppenheimer J, Anagnostou A, Shaker MS. Value-based care in allergy-immunology: Beyond the quality-adjusted life year. Allergy Asthma Proc. 2025 May 01; 46(3):165-167.
-
Patterson JK, Neuwahl S, Kirsch S, Moore JL, Tita ATN, Carlo WA, Lokangaka A, Tshefu A, Mwenechanya M, Chomba E, Kavi A, Metgud MC, Goudar SS, Derman RJ, Shivkumar P, Waikar M, Patel A, Hibberd PL, Nyongesa P, Esamai F, Ekhaguere OA, Bucher S, Jessani S, Tikmani SS, Saleem S, Wylie BJ, Goldenberg RL, Billah SM, Lennox R, Haque R, Petri WA, Mazariegos M, Krebs NF, Hemingway-Foday JJ, Babineau D, Koso-Thomas M, McClure EM, Bauserman M. Cost-effectiveness of intrapartum azithromycin to prevent maternal infection, sepsis, or death in low-income and middle-income countries: a modelling analysis of data from a randomised, multicentre, placebo-controlled trial. Lancet Glob Health. 2025 Apr; 13(4):e679-e688.
-
Gidwani R, Saylor KW, Russell LB. Health State Utility Values: The Implications of Patient versus Community Ratings in Assessing the Value of Care. Med Decis Making. 2025 May; 45(4):347-357.
-
Alba C, Malhotra S, Horsfall S, Barnhart ME, Bekker A, Chapman K, Cunningham CK, Fast PE, Fouda GG, Freedberg KA, Goga A, Ghazaryan LR, Leroy V, Mann C, McCluskey MM, McFarland EJ, Muturi-Kioi V, Permar SR, Shapiro R, Sok D, Stranix-Chibanda L, Weinstein MC, Ciaranello AL, Dugdale CM. Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for infants born in settings with high HIV burdens. PLoS One. 2025; 20(3):e0318940.
-
Sanders J, Conway AE, Kartha N, Kumar BP, Oppenheimer J, Verdi M, Anagnostou A, Abrams EM, Blatman KSH, Greenhawt M, Shaker MS. Cost-effectiveness of shared decision-making in determining challenge setting for nonsevere food protein-induced enterocolitis syndrome. Ann Allergy Asthma Immunol. 2025 Jun; 134(6):706-712.e2.
-
Zemplenyi A, Leonard J, Wright GC, DiStefano MJ, Nair K, Anderson KE, McQueen RB. Innovative Payment Models for Sickle-Cell Disease Gene Therapies in Medicaid: Leveraging Real-World Data and Insights from CMMI's Gene Therapy Access Model. Pharmacoeconomics. 2025 May; 43(5):583-594.
-
Atherly A, Kline DM, Fink RM, Fischer SM. Economic Impact of the Apoyo con Cari?o Intervention: Improving Palliative Care for Hispanics with Serious Illness. J Palliat Med. 2025 May; 28(5):640-644.
-
DiStefano MJ, McQueen RB, Gao V, Klein MP, Snell-Bergeon JK, Polsky S. The Cost of Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Type 1 Diabetes Pregnancies in the United States: A Cost-Consequences Analysis Using Real-World Evidence. Diabetes Technol Ther. 2025 Apr; 27(4):329-333.
-
Lloyd M, Morton JI, Peters RL, Loke P, Ashley S, Shaker MS, Greenhawt M, Ademi Z, Tang MLK. Cost-Effectiveness of Oral Immunotherapy for Egg Allergy According to Age of Therapy Commencement. J Allergy Clin Immunol Pract. 2025 Mar; 13(3):619-629.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|